Boryung has challenged Novartis' patent for its leukemia treatment Tasigna (Nilotinib). If the patent avoidance challenge is successful, Boryung is expected to be able to aim for synergy with the previously released Glivec (Imatinib mesilate) generic.

According to the pharmaceutical industry on the 3rd, Boryung recently requested a passive confirmation of the scope of rights in all directions on four patents of Tasigna. Tasigna is protected by a total of five patents. These include use patents that expire in November 2030, formulations patents that expire in 2027, crystalline and salt patents that expire in July 2026, and material patents that expire in August 2023. Among them, material patents have bee